Harnessing Artificial Intelligence for the Management of Patients With GI Cancers
American Society of Clinical Oncology Educational Book · 2026-06 · 46 (3)
DOI: 10.1200/edbk-26-515754 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026-06. Verfasst von Lipika Goyal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cancer Center, Stanford School of Medicine, Stanford, CA. Hauptthemen laut MEDLINE: Artificial Intelligence, Gastrointestinal Neoplasms. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
Artificial intelligence (AI) has the potential of reshaping GI oncology by enabling more nuanced interpretation of complex clinical, imaging, and molecular data, while supporting more timely and patient-centered decisions. This article synthesizes perspectives across the GI cancer continuum, beginning with a framework for context-aware AI that emphasizes metadata, multimodal integration, and lifecycle quality and safety as foundations for trustworthy tools that clarify, rather than conceal, uncertainty. Next, AI in endoscopy is highlighted as an example in clinic practice, focusing on computer-aided detection and diagnosis systems that not only increase adenoma detection rates but also raise questions about surveillance burden, real-world effectiveness, and the balance between skill enhancement and potential deskilling of endoscopists. Another section explores how AI can help GI oncologists design, prioritize, and implement highly innovative clinical trials—particularly multi-omic and imaging-driven approaches—while envisioning a future in which far more patients participate in trials that align with their goals and values. The final section reviews emerging AI-enabled clinical trial matching pipelines, including large language model–based retrieval and prescreening tools that operate on real-world electronic health record and protocol data, and discusses challenges related to bias, privacy, explainability, and workflow integration. Together, these contributions argue that the greatest impact of AI in GI oncology will come from deliberately aligning technical capabilities with highly relevant patient-centered clinical questions, ethical governance, and implementation strategies that expand access to trials and improve outcomes for patients with GI malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Stanford Cancer Center, Stanford School of Medicine, Stanford, CA.
- Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
- Clinical Effectiveness Research Group, University of Oslo and Oslo University Hospital, Oslo, Norway.
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI.
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.
- University of California San Francisco, San Francisco, CA.
ORCID-Profile: Mary Feng
Zitieren
APA
Goyal, L., Chung, C., Mori, Y., Hall, W. A., Kehl, K. L., & Feng, M. (2026). Harnessing Artificial Intelligence for the Management of Patients With GI Cancers. American Society of Clinical Oncology Educational Book, 46(3). https://doi.org/10.1200/edbk-26-515754
Vancouver
Goyal L, Chung C, Mori Y, Hall WA, Kehl KL, Feng M. Harnessing Artificial Intelligence for the Management of Patients With GI Cancers. American Society of Clinical Oncology Educational Book. 2026;46(3). doi:10.1200/edbk-26-515754
BibTeX
@article{Goyal2026,
author = {Goyal, Lipika and Chung, Caroline and Mori, Yuichi and Hall, William A and Kehl, Kenneth L and Feng, Mary},
title = {Harnessing Artificial Intelligence for the Management of Patients With GI Cancers},
journal = {American Society of Clinical Oncology Educational Book},
year = {2026},
volume = {46},
number = {3},
doi = {10.1200/edbk-26-515754}
}
EUVIMED